Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

81. Anticoagulant treatment for subsegmental pulmonary embolism.

Anticoagulant treatment for subsegmental pulmonary embolism. BACKGROUND: Acute pulmonary embolism (PE) is a common cause of death, accounting for 50,000 to 200,000 deaths annually. It is the third most common cause of mortality among the cardiovascular diseases, after coronary artery disease and stroke.The advent of multi-detector computed tomographic pulmonary angiography (CTPA) has allowed better assessment of PE regarding visualisation of the peripheral pulmonary arteries, increasing its (...) rate of diagnosis. More cases of peripheral PEs, such as isolated subsegmental PE (SSPE) and incidental PE, have thereby been identified. These two conditions are usually found in patients with few or none of the classic PE symptoms such as haemoptysis or pleuritic pain, acute dyspnoea or circulatory collapse. However, in patients with reduced cardio-pulmonary (C/P) reserve the classic PE symptoms can be found with isolated SSPEs. Incidental SSPE is found casually in asymptomatic patients, usually

Cochrane2016

82. Should Patients Who Receive a Diagnosis of Acute Pulmonary Embolism and Have Evidence of Right Ventricular Strain Be Treated With Thrombolytic Therapy?

Should Patients Who Receive a Diagnosis of Acute Pulmonary Embolism and Have Evidence of Right Ventricular Strain Be Treated With Thrombolytic Therapy? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2016

83. Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Sufficient Sensitivity to Identify Patients at Very Low Risk of Death?

Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Sufficient Sensitivity to Identify Patients at Very Low Risk of Death? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2016

84. Formative assessment and design of a complex clinical decision support tool for pulmonary embolism

Formative assessment and design of a complex clinical decision support tool for pulmonary embolism Formative assessment and design of a complex clinical decision support tool for pulmonary embolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Formative assessment and design of a complex clinical decision support tool for pulmonary embolism Article Text Methods Formative assessment and design of a complex clinical decision support tool for pulmonary embolism Sundas Khan , Lauren McCullagh , Anne Press , Manish Kharche , Andy Schachter , Salvatore

Evidence-Based Medicine (Requires free registration)2016

85. Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ?trigger rates?

Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ?trigger rates? Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ‘trigger rates’ | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ‘trigger rates’ Article Text Original EBM Research Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ‘trigger rates’ Statistics from Altmetric.com You do not have access

Evidence-Based Medicine (Requires free registration)2016

86. Suspected Pulmonary Embolism

Suspected Pulmonary Embolism Revised 2016 ACR Appropriateness Criteria® 1 Suspected Pulmonary Embolism American College of Radiology ACR Appropriateness Criteria ® Suspected Pulmonary Embolism Variant 1: Suspected pulmonary embolism. Intermediate probability with a negative D-dimer or low pretest probability. Radiologic Procedure Rating Comments RRL* X-ray chest 9 ? CTA chest with IV contrast 5 This procedure should be optimized for pulmonary arterial enhancement. This procedure may (...) contrast 2 O US echocardiography transthoracic resting 2 O CT chest without and with IV contrast 1 ??? Arteriography pulmonary with right heart catheterization 1 ???? MRA chest without IV contrast 1 O US echocardiography transesophageal 1 O Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Suspected Pulmonary Embolism Variant 2: Suspected pulmonary embolism. Intermediate probability with a positive

American College of Radiology2016

87. Edoxaban (Lixiana) - Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Edoxaban (Lixiana) - Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Scottish Medicines Consortium2015

88. Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months?

Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? BestBets: Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Report By: Chris Morgan - Medical Student Y5 Search checked by Rick Body - Consultant in Emergency Medicine Institution: University of Manchester, Manchester, UK Original institution: Manchester Royal Infirmary Date Submitted: 21st October 2015 (...) Date Completed: 21st October 2015 Last Modified: 21st October 2015 Status: Green (complete) Three Part Question In [patients with proven pulmonary embolism (PE)] is [Rivaroxaban better than warfarin] at [reducing mortality and recurrence of venous thromboembolism at 6 months]? Clinical Scenario A 52-year-old lady has presented to the Emergency Department with a suspected PE. This is confirmed by CT pulmonary angiography (CTPA). Consequently she requires anticoagulation. Hospital guidelines suggest

BestBETS2015

89. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.

Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. DESCRIPTION: Pulmonary embolism (PE) can be a severe disease and is difficult to diagnose, given its nonspecific signs and symptoms. Because of this, testing patients with suspected acute PE has increased dramatically. However, the overuse of some tests, particularly computed tomography (CT) and plasma d-dimer measurement, may (...) not improve care while potentially leading to patient harm and unnecessary expense. METHODS: The literature search encompassed studies indexed by MEDLINE (1966-2014; English-language only) and included all clinical trials and meta-analyses on diagnostic strategies, decision rules, laboratory tests, and imaging studies for the diagnosis of PE. This document is not based on a formal systematic review, but instead seeks to provide practical advice based on the best available evidence and recent guidelines

Annals of Internal Medicine2015 Full Text: Link to full Text with Trip Pro

90. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism Edo Edoxaban for treating and for pre xaban for treating and for prev venting enting deep v deep vein thrombosis and pulmonary ein thrombosis and pulmonary embolism embolism T echnology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta354 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) , to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - edoxaban tosylate (TA354) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions

National Institute for Health and Clinical Excellence - Technology Appraisals2015

91. Fibrinolysis for patients with intermediate-risk pulmonary embolism

Fibrinolysis for patients with intermediate-risk pulmonary embolism PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2015

92. Do patients with a clinically suspected subsegmental pulmonary embolism need anticoagulation therapy?

Do patients with a clinically suspected subsegmental pulmonary embolism need anticoagulation therapy? BestBets: Do patients with a clinically suspected subsegmental pulmonary embolism need anticoagulation therapy? Do patients with a clinically suspected subsegmental pulmonary embolism need anticoagulation therapy? Report By: Chris Morgan, Hyun Choi - TBC Institution: University of Manchester, Manchester, UK and Emergency Department, Lewisham and Greenwich NHS Trust, London, UK Date Submitted (...) : 26th August 2015 Last Modified: 26th August 2015 Status: Green (complete) Three Part Question In [a symptomatic patient with an isolated subsegmental pulmonary embolism] does [anticoagulation therapy or no treatment] lead to [lower rates of mortality and recurrent venous thromboembolism?] Clinical Scenario A 62-year-old gentleman attends your Emergency Department with shortness of breath and chest pain. You suspect a pulmonary embolism (PE) and request a CT pulmonary angiogram. The radiologist

BestBETS2015

93. Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism

Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism 25633724 2015 07 07 2015 09 21 2015 07 07 1931-3543 148 1 2015 Jul Chest Chest Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism. 211-8 10.1378/chest.14-2551 For patients with acute symptomatic pulmonary embolism (PE), the Bova score (...) classifies their risk for PE-related complications within 30 days after diagnosis. The original Bova score was derived from 2,874 normotensive patients with acute PE who participated in one of six prospective PE studies. We retrospectively assessed the validity of the Bova risk model in normotensive patients with acute PE diagnosed in an academic urban ED. Two clinician investigators used baseline data for the model's four prognostic variables to stratify patients into the three Bova risk stages (I-III

EvidenceUpdates2015

94. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. 26151264 2015 07 08 2015 07 23 2016 10 17 1538-3598 314 1 2015 Jul 07 JAMA JAMA Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. 31-40 10.1001/jama.2015.7046 The optimal duration of anticoagulation after a first episode of unprovoked pulmonary embolism is uncertain. To determine (...) the benefits and harms of an additional 18-month treatment with warfarin vs placebo, after an initial 6-month nonrandomized treatment period on a vitamin K antagonist. Randomized, double-blind trial (treatment period, 18 months; median follow-up, 24 months); 371 adult patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist were randomized

JAMA2015 Full Text: Link to full Text with Trip Pro

95. Comparison of Wells and Revised Geneva Rule to Assess Pretest Probability of Pulmonary Embolism in High-Risk Hospitalized Elderly Adults

Comparison of Wells and Revised Geneva Rule to Assess Pretest Probability of Pulmonary Embolism in High-Risk Hospitalized Elderly Adults 26032745 2015 06 22 2015 09 11 2015 06 22 1532-5415 63 6 2015 Jun Journal of the American Geriatrics Society J Am Geriatr Soc Comparison of Wells and Revised Geneva Rule to Assess Pretest Probability of Pulmonary Embolism in High-Risk Hospitalized Elderly Adults. 1091-7 10.1111/jgs.13459 To assess and compare the diagnostic power for pulmonary embolism (PE) of (...) Wells and revised Geneva scores in two independent cohorts (training and validation groups) of elderly adults hospitalized in a non-emergency department. Prospective clinical study, January 2011 to January 2013. Unit of Internal Medicine inpatients, University of Catania, Italy. Elderly adults (mean age 76 ± 12), presenting with dyspnea or chest pain and with high clinical probability of PE or D-dimer values greater than 500 ng/mL (N = 203), were enrolled and consecutively assigned to a training (n

EvidenceUpdates2015

96. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism Apixaban for the treatment and Apixaban for the treatment and secondary pre secondary prev vention of deep v ention of deep vein ein thrombosis and/or pulmonary embolism thrombosis and/or pulmonary embolism T echnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta341 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions (...) due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341) © NICE 2018. All rights reserved

National Institute for Health and Clinical Excellence - Technology Appraisals2015

97. Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism

Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism Ultr Ultrasound-enhanced, catheter-directed asound-enhanced, catheter-directed thrombolysis for pulmonary embolism thrombolysis for pulmonary embolism Interventional procedures guidance Published: 26 June 2015 nice.org.uk/guidance/ipg524 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) thrombolysis for pulmonary embolism raises no major safety concerns over those of catheter-directed thrombolysis (CDT) alone. With regard to efficacy, evidence of any enhancement of thrombolysis over CDT alone is inadequate in quality © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 8and quantity. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit

National Institute for Health and Clinical Excellence - Interventional Procedures2015

98. Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism

Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism Prescrire IN ENGLISH - Spotlight ''In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism'', 1 June 2015 {1} {1} {1} | | > > > In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |  (...)  |   |   |   |   |  Spotlight In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism FREE DOWNLOAD In the New Products section of the June issue: compared with adjusted-dose warfarin, dabigatran provides no tangible advantages for patients with pulmonary embolism or deep vein thrombosis. Warfarin remains the standard drug. Full text available for free download. Summary The anticoagulant dabigatran

Prescrire2015

99. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study 25716463 2015 03 10 2015 08 12 2017 02 20 1553-2712 22 3 2015 Mar Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE (...) study. 299-307 10.1111/acem.12615 The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients. A post hoc analysis of EINSTEIN PE data was performed to assess the efficacy and safety of rivaroxaban in patients with a range of simplified

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

100. Should we use an age adjusted D-dimer threshold in managing low risk patients with suspected pulmonary embolism?

Should we use an age adjusted D-dimer threshold in managing low risk patients with suspected pulmonary embolism? BestBets: Should we use an age adjusted D-dimer threshold in managing low risk patients with suspected pulmonary embolism? Should we use an age adjusted D-dimer threshold in managing low risk patients with suspected pulmonary embolism? Report By: Dr Tom Jaconelli - Registrar in Emergency Medicine Search checked by Dr Steven Crane - Consultant in Emergency Medicine Institution: York (...) District Hospital, York, UK Date Submitted: 26th December 2014 Date Completed: 6th May 2015 Last Modified: 6th May 2015 Status: Green (complete) Three Part Question In [patients with signs and symptoms of pulmonary embolism who are deemed low risk] is a [age adjusted D-dimer sensitive enough] compared to a standard D-dimer to [safely exclude pulmonary embolism]? Clinical Scenario A70 year old man presents with pleuritic chest pain. A D-dimer taken at triage is mildly elevated from the standard positive

BestBETS2015